Get the Stockscreener App
0.4741
8.47%
-0.0439
Pre-market:
.47
-0.0041
-0.86%
Carisma Therapeutics Inc stock is traded at $0.4741, with a volume of 119.20K.
It is down -8.47% in the last 24 hours and down -39.38% over the past month.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
See More
Previous Close:
$0.518
Open:
$0.52
24h Volume:
119.20K
Relative Volume:
0.49
Market Cap:
$19.79M
Revenue:
$14.92M
Net Income/Loss:
$-86.88M
P/E Ratio:
-0.1382
EPS:
-3.43
Net Cash Flow:
$-82.31M
1W Performance:
+7.73%
1M Performance:
-39.38%
6M Performance:
-58.04%
1Y Performance:
-83.01%
1-Day Range:
$0.4678
$0.52
1-Week Range:
$0.44
$0.6179
52-Week Range:
$0.38
$2.94
Carisma Therapeutics Inc Stock (CARM) Company Profile
Name
Carisma Therapeutics Inc
Sector
Industry
Phone
(267) 491-6422
Address
3675 MARKET STREET, PHILADELPHIA
Compare CARM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.4741 | 19.79M | 14.92M | -86.88M | -82.31M | -3.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-10-24 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-11-24 | Initiated | BTIG Research | Buy |
| Oct-03-23 | Initiated | CapitalOne | Overweight |
| Jul-06-23 | Initiated | Evercore ISI | Outperform |
| May-31-23 | Upgrade | Jefferies | Hold → Buy |
| May-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
View All
Carisma Therapeutics Inc Stock (CARM) Latest News
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of “Hold” from Analysts - Defense World
Barclays PLC Grows Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 - GuruFocus.com
4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology - Quantisnow
Carisma Therapeutics Appoints Interim VP of Finance - TipRanks
Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization - MSN
Carisma downgraded by H.C. Wainwright to neutral - MSN
Carisma Therapeutics (NASDAQ:CARM) Given Neutral Rating at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Carisma Therapeutics (CARM) - MSN
Carisma Therapeutics (NASDAQ:CARM) Cut to Neutral at Robert W. Baird - Defense World
Carisma downgraded by Baird over lack of near-term catalysts - MSN
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Kilgore News Herald
Baird Downgrades Carisma Therapeutics (CARM) - MSN
BTIG cuts Carisma Therapeutics to Neutral from Buy By Investing.com - Investing.com Nigeria
Carisma downgraded by Baird over lack of near-term catalysts (CARM:NASDAQ) - Seeking Alpha
Carisma Therapeutics downgraded to Neutral from Outperform at Baird - MSN
BTIG Downgrades Carisma Therapeutics (CARM) - MSN
Evercore ISI Group Downgrades Carisma Therapeutics (CARM) - MSN
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 - The Eastern Progress Online
Carisma Therapeutics cut to In Line, stock target slashed on tempered outlook - Investing.com
Carisma Therapeutics Drops GC As Part Of Cutbacks - Law360
Carisma Therapeutics Announces Strategic Restructuring to Re-Prioritize Pipeline and A Reduction in the Workforce by 34% - Marketscreener.com
Carisma Therapeutics shifts focus, cuts workforce by 34% - Investing.com Nigeria
BTIG cuts Carisma Therapeutics to Neutral from Buy - Investing.com
Penn spinout Carisma Therapeutics to narrow R&D focus, lay off more than a third of its workforce - The Business Journals
Carisma Therapeutics shifts focus, cuts workforce by 34% By Investing.com - Investing.com South Africa
Carisma Therapeutics Reprioritizes Pipeline, Cuts Jobs - Contract Pharma
Carisma Therapeutics Announces Strategic Restructuring to Re-pri - GuruFocus.com
Carisma Therapeutics Restructures Amid Strategic Refocus - TipRanks
Carisma Therapeutics Pivots Strategy, Cuts 34% of Workforce to Focus on Macrophage Platform - StockTitan
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma - The Eastern Progress Online
Carisma Therapeutics to Present at Upcoming Conferences - The Eastern Progress Online
Carisma Therapeutics Announces Changes to its Board of Directors - The Eastern Progress Online
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28% - Simply Wall St
CARM Stock Hits 52-Week Low at $0.8 Amid Market Challenges - Investing.com
Carisma Therapeutics CEO to Speak at 7th Annual Evercore ISI HealthCONx Conference - MSN
Carisma Therapeutics Announces Upcoming Presentations at SITC 20 - GuruFocus.com
Carisma Therapeutics stock target cut, maintains buy on clinical trial - Investing.com
Carisma Therapeutics stock target cut, maintains buy on clinical trial By Investing.com - Investing.com Canada
Carisma Therapeutics price target lowered to $5 from $8 at H.C. Wainwright - TipRanks
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CA - GuruFocus.com
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com
Carisma Therapeutics Reports Q3 2024 Results, Advances Clinical Programs - MSN
Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy - MSN
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 - PR Newswire
Carisma Therapeutics Inc Stock (CARM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):